Pharmascience, a generic pharmaceutical company, announced today that it has acquired Aegera Therapeutics Inc., a Montreal based clinical-stage biotechnology company focused on developing targeted therapeutics to address thus far unmet major medical needs primarily in oncology.
Financial terms were not disclosed. Aegera’s 20 plus employees will join Pharmascience.
Aegera Therapeutics and its wholly-owned Ontario subsidiary, Aegera Oncology Inc., had raised over $Subscriber content million from its venture capital (VC) backers. Its last major financing closed in December 2007.
Aegera’s backers included The VenGrowth Advanced Life Sciences Fund Inc., Capital régional et coopératif Desjardins, GrowthWorks Canadian Fund Ltd., Fonds de solidarité FTQ, Human Genome Sciences, Inc. (NASDAQ: HGSI), Fondaction, le Fonds de développement de la CSN pour la coopération et l’emploi, GeneChem Therapeutics Venture Fund LP, BDC Venture Capital, Lothian Partners 27 (sarl) SICAR (formerly Innovatech du Grand Montréal), Caisse de dépôt et placement du Québec/Sofinov, T2C2/Bio 2000 LP, Neuroscience Partners, and MedTech Partners.
Capital régional et coopératif Desjardins, GrowthWorks Canadian Fund Ltd., Fonds de solidarité FTQ, and Fondaction reported their investments (at cost) as $Subscriber content million respectively.
VenGrowth, an Ontario based labour sponsored investment fund (LSIF), held its investment in Ottawa based Aegera Oncology Inc. as an eligible LSIF investment. It reported its investment at $Subscriber content million, representing approximately 22% of its net asset value.
